Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELI 002

X
Drug Profile

ELI 002

Alternative Names: AMP KRAS; AMP-CpG; Amph-CpG-7909; Amphiphile mKRAS vaccine; Amphiphile-CpG; ELI-002; ELI-002 2P; ELI-002 7P; VED-002

Latest Information Update: 30 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elicio Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 23 May 2024 Preliminary efficacy and adverse events data from the phase I/II AMPLIFY-7P trial in Solid tumours released by Elicio Therapeutics
  • 09 Jan 2024 Adverse events data from a phase I/II trial in Solid tumor released by Elicio Therapeutics
  • 09 Jan 2024 Efficacy and adverse event data from a phase I/II trial in Pancreatic cancer, Non-small cell lung cancer, Colorectal cancer, Ovarian cancer, Gallbladder cancer, and Cholangiocarcinoma released by Elicio Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top